Your session is about to expire
← Back to Search
Cefiderocol for Sepsis
Study Summary
This trial is designed to study how well a new antibiotic works in patients on ECMO.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 300 Patients • NCT03032380Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there currently an opportunity for participants to enroll in this trial?
"Affirmative. Clinicaltrials.gov reveals that this clinical trial is currently calling for participants, having been first published on July 16th 2021 and most recently updated on August 3rd 2022. The study requires 8 volunteers from a single medical centre to partake in the research."
What is the participant capacity of this investigation?
"Affirmative. According to the information provided on clinicaltrials.gov, this medical trial has been open for recruitment since July 16th 2021 and was recently amended August 3rd 2022 with a goal of recruiting 8 participants at 1 location."
What health issues may be addressed through Cefiderocol?
"Infections such as pyelonephritis, nosocomial pneumonia, and bacterial pneumonia can all be managed through the use of Cefiderocol."
Which other experiments have been performed to evaluate Cefiderocol's efficacy?
"Currently, 4 clinical studies are underway to research Cefiderocol, with none of them reaching the third phase. Hartford hosts most of these trials; however, 84 other medical facilities have taken part in this investigation as well."
Has the FDA sanctioned Cefiderocol for therapeutic applications?
"The safety of Cefiderocol earned a score of 1 due to the preliminary nature of this Phase 1 trial, meaning there is limited data proving its efficacy and overall safety."
Is this trial a pioneering endeavor in the medical field?
"Since 2019, Shionogi has been sponsoring research into Cefiderocol. After their initial trial involving 439 subjects in the same year, this drug was granted Phase 2 approval and there are currently four active trials across 10 cities and 21 countries."
Share this study with friends
Copy Link
Messenger